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The Consortium for Blood Group Genes (CBGG) is
a worldwide organization whose goal is to have a
system to interact, establish standards, operate a
proficiency program, and provide education for
laboratories involved in DNA and RNA testing for the
determination of blood group, platelet, and neutrophil
antigens. The purpose of this report is to summarize
the CBGG meeting held in Miami in October 2006.
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The Consortium for Blood Group Genes (CBGG)
was started by a group of people interested in DNA
analyses for blood groups who recognized that there
was a growing need for establishing standard protocols
and proficiency testing. The current coordinator is
Marion Reid, and there are three liaisons:Lilian Castilho
for Brazil, Gregory Denomme for Canada, and Connie
Westhoff for the United States. All members are
expected to interact and participate. The background
and progress, including CBGG logo, history, and
mission, have been published.1,2 The CBGG is a
nonprofit organization whose purpose is to provide a
means for members to interact, educate, and help each
other. Exchange of information is mainly accomplished
through electronic mailings and the AABB Special
Interest Group (SIG) Molecular Forum. (To access this
SIG, log on to the AABB website as an AABB member,
choose “AABB Forums,” and then scroll down to “Hot
Topics Section”).
Discussion Document
A discussion document was circulated to all
members before the meeting and was addressed by the
group at the meeting. The information given in the
descriptive history, structure, language, membership,
mission, and goals sections was accepted with minor
changes. The key areas of focus that had been
identified by CBGG for discussion at the 2006 Miami
meeting were discussed and are summarized here. The
2006 Discussion Document will be archived for
reference purposes. Suggestions from the group
present and from those who sent electronically mailed
comments will be incorporated into the document.
The updated 2007 version will be distributed to CBGG
members before the 2007 meeting and is available to
nonmembers on request.
Establish a uniform terminology
Of major interest to the group is a uniform
terminology for alleles encoding blood group antigens
and phenotypes. Standards exist for the terminology of
nucleic acid and amino acid changes (http://www.
hgvs.org/mutnomen/). Also, as a detailed and consis-
tent system for naming blood group alleles is being
addressed by an ad hoc group of the International
Society of Blood Transfusion Working Party on
Terminology for Red Cell Surface Antigens, of which
several CBGG members are also members, it was
decided to wait for and adopt their recommendations.
Develop template disclaimers
Disclaimer statements used by CBGG members
when reporting results of home-brew DNA analysis for
blood groups were solicited before the meeting. A
draft generic disclaimer statement for use in clinical
reports was developed by the group, which members
then submitted to their legal departments for
suggestions and approval. It reads:
These in vitro diagnostic tests were developed
and their performance characteristics
established by <<facility name>>. The tests
have not been cleared or approved by the Food
and Drug Administration (FDA). <<Facility
name>> is certified under the Clinical
Laboratory Improvement Amendment (CLIA)
of 1988 as qualified to perform high
complexity clinical testing. These results are
not intended as the sole means for clinical
diagnosis or patient management decisions.
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There are situations where the genotype of a
person may not reflect the red cell phenotype
and not all performance characteristics have
been determined. Mutations that inactivate
gene expression or rare new variant alleles may
not be identified in these assays.
Comments by legal counsel will be shared at the
2007 meeting, and a consensus disclaimer prepared for
discussion before distributing the final version.
Identify sources of funding
Sources of funding were discussed. The group
agreed that a nominal membership fee is appropriate,
the amount and format (e.g., institution versus
individual) to be determined. The funds will be used
for meeting room rentals and refreshments. Other
sources of funding that were identified included a fee
for participating in the proficiency program and for
shipping DNA from the repository (see discussion in a
later section). The possibility of obtaining education
money through the AABB or meeting funds through
the National Institutes of Health R13 funding
mechanism needs to be investigated, although it was
thought they may not be appropriate. It remains to be
decided in which country or state the treasury should
reside. To minimize expenses, the 2007 meetings will
be held in conjunction with an International
Immunohematology Symposium in Sao Paulo, Brazil,
and the International Conference of Investigative
Immunohematologists meeting in North Carolina. The
2008 meeting will be held before the AABB meeting in
Montreal.
Develop standards of practice
Before the meeting, a survey was circulated about
standards. All responders,except one abstention,voted
for the CBGG to set standards, and all, except one
abstention, voted that the CBGG should not accredit
laboratories. At the meeting, there was discussion
about the role of CBGG in setting standards, and it
was agreed that although this is not an “official”
organization, a consensus was reached that it would be
useful to members of the CBGG to have standards, at
least in a self-help capacity. Because of the
international membership, draft standards have been
written in International Standards Organization format,
and after the Miami meeting, they were disseminated to
CBGG members for input.
Expand and operate a proficiency program
A simple exchange of samples between several
laboratories performing home-brew DNA assays is in
effect. Samples are exchanged in the spring and fall.
DNA from one sample is sent for testing for one
defined single nucleotide polymorphism for which the
predicted antigen had been confirmed by hemagglu-
tination, with the caveat that the proficiency exercise
would not involve rare alleles and should be straight-
forward. Results obtained by the testing laboratories
are returned to the laboratory that sent the sample(s),
and the shipping laboratory confirms (or not) the
results and interpretation. Currently, the New York
Blood Center (NYBC) is the central coordinating
facility.
Establish a DNA repository of well-characterized
DNA
Members agreed that the best source of DNA for
reference samples for proficiency, validation, and
control samples is from transformed cell lines. It was
recognized that not all members have the ability to
establish cell lines. Currently, NYBC in New York,
American Red Cross Blood Services in Philadelphia,
and Puget Sound Blood Center in Seattle have access to
the required technology and would make DNA
available to those who do not. Ultimately, a compre-
hensive collection of samples would be established,
which would include common and rare samples for
new assay development and validation. Until suitable
rare donors can be obtained for the preparation of cell
lines, DNA isolated from blood samples could be
available for validation purposes. DNA samples should
be those in which the genotype has been confirmed
(preferably by sequencing) by the source laboratory.
The criteria for establishing the validity of these
samples will be developed. Institutional review board
(IRB) approval may be required for obtaining blood
samples for this purpose and is certainly required if
publishing any results related to this function. The cost
to maintain the repositories is to be determined.
Regulatory and informed consent issues
Predicting the presence or absence of a blood
group antigen using a DNA assay is not genotyping for
a disease; it is considered an alternative method to
serologic testing. When such testing is performed for
patient care, which includes typing patients and
donors, IRB approval and informed consent are
typically not required.
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Attention SBB and BB Students: You are eligible for a free 1-year subscription to Immunohematology. Ask
your education supervisor to submit the name and complete address for each student and the inclusive dates
of the training period to Immunohematology, P.O. Box 40325, Philadelphia, PA 19106.
A representative of the FDA attends CBGG
meetings. In September 2006, the FDA held a meeting
entitled, “Molecular Methods in Immunohematology.”
Transcripts from talks given at this meeting are
available online at: http://www.fda.gov/cber/minutes/
workshop-min.htm#immuno and slides from presen-
tations are at: http://www.fda.gov/cber/summaries.
htm#stats.
Consensus panel of markers
The value of developing a consensus panel of DNA
assays, based on ranking clinically significant markers
for minor blood groups and developing a“compatibility
score,”was discussed.
Conclusion
The CBGG is a self-help, nonprofit, organization
designed for members to learn from each other.
Anyone interested in molecular testing for blood
groups and willing to contribute intellectually is
welcome to join. To become a member,contact Marion
Reid (mreid@nybloodcenter.org), Lilian Castilho
(castilho@unicamp.br), Greg Denomme (greg.
denomme@bloodservices.ca), or Connie Westhoff
(WesthoffC@usa.redcross.org).
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